ADV6209 is an oral liquid solution developed by Advicenne for moderate sedation, originally developed in collaboration with the University Hospital of Amiens (CHU Amiens-Picardie).
This product has been specially designed for children to significantly reduce their anxiety and to improve their immobility when undertaking stressful or painful medical, therapeutic or diagnostic procedures. It is the only oral midazolam in liquid form which would be suitable and indicated for children older than six months approved.
In March 2016, Advicenne sold ADV6209 to Primex Pharmaceuticals, a Swiss company, in a global deal worth several tens of millions of euros. The sale entailed a significant upfront payment and subsequent milestones and royalties.
Marketing authorization for ADV6209 was granted on 12 September 2018.
Advicenne has been commercializing Likozam® in France since February 2016. A product in-licensed from Rosemont Pharmaceuticals, Likozam® is designed to treat partial and generalized chronic refractory epilepsy in children and adults.
It is the only product available on the market for refractory epilepsy in a liquid form that is suitable and indicated for children six years old or younger and for people with swallowing difficulties.
Advicenne has been commercializing Levidcen® in France since October 2015. A product in-licensed from Desitin GmbH, Levidcen® is designed to treat epileptic patients with partial-onset seizures and is suitable for both children and adults.
Levidcen® is a granulated, two-millimeter formulation of levetiracetam that is tasteless and has been specifically adapted for children and patients with swallowing difficulties. Other formulations of levetiracetam are either liquids with a repulsive taste, which may reduce patient compliance, or large tablets of approximately thirteen to nineteen millimeters, which are not suitable for patients with swallowing difficulties.
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2019 Advicenne